Cellectar Biosciences (NASDAQ:CLRB) announced its earnings results on Monday. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.24, Bloomberg Earnings reports.
CLRB stock opened at $2.19 on Tuesday. Cellectar Biosciences has a 52-week low of $1.22 and a 52-week high of $4.28. The business’s fifty day simple moving average is $2.15. The company has a quick ratio of 5.04, a current ratio of 5.04 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $20.86 million, a PE ratio of -0.47 and a beta of 1.17.
A number of equities research analysts have commented on the company. HC Wainwright assumed coverage on Cellectar Biosciences in a report on Thursday, May 2nd. They set a “buy” rating and a $4.00 target price on the stock. ValuEngine upgraded Cellectar Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research cut Cellectar Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 2nd. Finally, Brookline Capital Management initiated coverage on Cellectar Biosciences in a report on Monday, July 29th. They set a “buy” rating and a $6.00 price objective on the stock.
Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM.
Further Reading: Certificate of Deposit (CD)
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.